Abstract:
:Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresponder patients. microRNAs (miRs) have been used as AF fibrotic and electrical alterations biomarkers. miRs may differentiate responders patients to ablative approach. Selective miR target therapy, as upregulation by adenovirus transfection and/or miR downregulation by antagomiR, may be used to treat AF patients. Catheter ablation of triggering electrical pulmonary veins activity or fibrotic areas defragmentation may be upgraded by miR therapy to prevent cardiac electrical and fibrotic remodeling after AF ablation.
journal_name
Pharmacogenomicsjournal_title
Pharmacogenomicsauthors
Sardu C,Santamaria M,Paolisso G,Marfella Rdoi
10.2217/pgs.15.117subject
Has Abstractpub_date
2015-11-01 00:00:00pages
1863-77issue
16eissn
1462-2416issn
1744-8042journal_volume
16pub_type
杂志文章,评审相关文献
PHARMACOGENOMICS文献大全abstract::High-throughput genotyping approaches are being developed to meet the demands of pharmacogenomnics, where numerous individuals are studied with thousands of single nucleotide polymorphism (SNP) markers. All non-gel-based genotyping approaches achieve allelic discrimination by one of four mechanisms: allele-specific hy...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.1.1.95
更新日期:2000-02-01 00:00:00
abstract::Pharmacogenomics seeks to understand the genetic basis of interindividual differences in drug disposition and effects. Differential drug response is likely to most often be a complex trait, in which multiple genes contribute with varying strengths to the therapeutic phenotype. Due to technical and economic limitations...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.6.781
更新日期:2002-11-01 00:00:00
abstract::Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & methods: Brazilian kidney recipients were treated with TAC combined with everolimus (n = 178) or mycophenolate sodium (n = 97). The variants in CYP...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2019-0120
更新日期:2020-01-01 00:00:00
abstract::This review will summarize the role of pharmacogenetics in the natural history of hepatitis C, particularly in patients with HIV/HCV and will take the perspective of pharmacogenetics and its influence on the response to antiviral therapy and the susceptibility to develop adverse effects. This review will also devote a...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2018-0046
更新日期:2018-08-01 00:00:00
abstract::Evaluating the prospects for 'personalized healthcare' has become topical at the 10-year anniversary of the first results from the Human Genome Project. The coincidence of this milestone with a period of global financial difficulty is unfortunate, but industry has signaled its willingness to invest in this new medical...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.12.143
更新日期:2012-11-01 00:00:00
abstract::The recent advent of induced pluripotent stem cells has enabled the study of patient-specific and disease-related neurons in vitro and has facilitated new directions of inquiry into disease mechanisms. With these approaches, we now have the possibility of correlating ex vivo cellular phenotypes with individual patient...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2016-0187
更新日期:2017-04-01 00:00:00
abstract::Pharmacogenomics examines how the benefits and adverse effects of a drug vary among patients in a target population by analyzing genomic profiles of individual patients. Personalized medicine prescribes specific therapeutics that best suit an individual patient. Much current research focuses on developing genomic biom...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.13.75
更新日期:2013-06-01 00:00:00
abstract:INTRODUCTION:Marked lowering of low-density-lipoprotein cholesterol (LDL-C) levels (< or =50%) with intensive statin therapy is associated with major reduction in cardiovascular risk, but is limited by a potential increase in adverse effects, thereby justifying optimization of LDL-C reduction with minimal risk. The org...
journal_title:Pharmacogenomics
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2217/14622416.9.9.1217
更新日期:2008-09-01 00:00:00
abstract:AIM:GLP-1 plays a key role in glucose metabolism and influences antipsychotic-induced weight gain (AIWG). Our study is the first to investigate the encoding gene, GCG, and the GLP-1 receptor gene, GLP1R, and association with AIWG. MATERIALS & METHODS:In 216 schizophrenic patients treated with antipsychotics for up to ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.247
更新日期:2014-03-01 00:00:00
abstract::Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.09.10
更新日期:2009-04-01 00:00:00
abstract:AIMS:Carvedilol is an effective treatment in hypertension and chronic heart failure. The medical impact of polymorphisms in CYP2D6 and in the β-adrenergic receptors ADRB1 and ADRB2 on the pharmacokinetics and pharmacodynamics of carvedilol is controversial. METHODS:After carvedilol 25 mg was administered to 110 volunt...
journal_title:Pharmacogenomics
pub_type: 临床试验,杂志文章
doi:10.2217/pgs.11.20
更新日期:2011-06-01 00:00:00
abstract::Hematopoietic stem cell transplantation (HSCT) is a curative treatment for several malignant and nonmalignant disorders. Busulfan (Bu) and cyclophosphamide (Cy) are the most commonly used alkylators in high-dose pretransplant conditioning for HSCT; a treatment that is correlated with drug-related toxicity and relapse....
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.12.185
更新日期:2013-01-01 00:00:00
abstract:AIM:This study aimed to assess the effectiveness of genotype-guided warfarin dosing. PATIENTS & METHODS:A total of 109 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information. Primary end points were th...
journal_title:Pharmacogenomics
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2217/pgs.13.145
更新日期:2013-10-01 00:00:00
abstract:AIM:To determine if copy number variants contribute to warfarin dose requirements, we investigated CYP2C9, VKORC1, CYP4F2, GGCX and CALU for deletions and duplications in a multiethnic patient population treated with therapeutic doses of warfarin. PATIENTS & METHODS:DNA samples from 178 patients were subjected to copy...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.11.156
更新日期:2012-02-01 00:00:00
abstract::Despite their clearly distinct pathophysiologies, HIV and cancer are diseases whose response to chemotherapy treatment varies substantially amongst patients, in particular for those with prior drug exposure. This has been attributed, in part, to elevated expression of the ABCB1 drug transporter in some patients, which...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.11.84
更新日期:2011-10-01 00:00:00
abstract:AIM:To determine the clinical and genetic predictors of the dipeptidyl peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus (T2DM) patients. PATIENTS & METHODS:DPP4, WFS1 and KCNJ11 gene polymorphisms were genotyped in a cohort study of 662 T2DM patients treated with DPP-4 inhibitors sitaglipti...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2016-0010
更新日期:2016-06-01 00:00:00
abstract::The 4th US FDA/Industry workshop, in a series on Pharmacogenomics, was on 'Biomarkers and Pharmacogenomics in Drug Development and Regulatory Decision Making' and was held on December 10-12, 2007 in Bethesda, MD, USA, with clear objectives to continue the dialogue that began in 2002 for enabling the use of biomarkers ...
journal_title:Pharmacogenomics
pub_type:
doi:10.2217/14622416.10.1.111
更新日期:2009-01-01 00:00:00
abstract::The response to lipid-lowering drugs is modified by a number of factors like age, gender, concomitant disease and genetic determinants. Even within homogenous groups of patients, individual responses vary greatly. Until now, no clinical or biochemical parameter exists which predicts whether a subject will respond well...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.2.2.107
更新日期:2001-05-01 00:00:00
abstract:INTRODUCTION:Warfarin is a widely prescribed, efficacious oral anticoagulant. S-warfarin, the more active form, is metabolized by the cytochrome P450 (CYP)2C9 enzyme. The aim was to evaluate the influence of two CYP2C9 functional polymorphisms (*2 and *3) on warfarin dose in African-Americans, an unstudied population a...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.8.3.217
更新日期:2007-03-01 00:00:00
abstract:AIMS:The importance of polymorphisms in the dihydropyrimidine dehydrogenase gene (DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU)-based chemotherapy is still unclear. This study aims to assess the predictive value of DPYD variation with respect to previously described DPYD variants for 5-FU toxicit...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.09.28
更新日期:2009-06-01 00:00:00
abstract:OBJECTIVES:Three exonic single nucleotide polymorphisms (SNPs) in the cytochrome P450 2B6 (CYP2B6) gene, 516G>T, 785A>G and 1459C>T, have been described to be associated with functional changes in the CYP2B6 catalytic activity or protein expression. They are therefore of potential clinical importance for drug efficacy ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.7.7.995
更新日期:2006-10-01 00:00:00
abstract::Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease susceptibility and 46 with impact in the clinical outcome of patients (p < 5.00 × 10-...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2017-0108
更新日期:2017-11-01 00:00:00
abstract::While different markers for cancer diagnosis have been known for at least a decade, the systematic search for biomarkers emerged only several years ago. In this article, I will concentrate on DNA methylation as a dynamic and robust platform for the development of cancer-specific biomarkers. Simultaneous analysis of a ...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.5.6.699
更新日期:2004-09-01 00:00:00
abstract::Fibrates are a medication class prescribed for decades as 'broad-spectrum' lipid-modifying agents used to lower blood triglyceride levels and raise high-density lipoprotein cholesterol levels. Such lipid changes are associated with a decrease in cardiovascular disease, and fibrates are commonly used to reduce risk of ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2019-0140
更新日期:2020-03-01 00:00:00
abstract::Human cytochrome P450 (CYP)3A is a major P450 enzyme found in the liver and gastrointestinal tract. It plays an important role in the metabolism of a wide variety of drugs, some endogenous steroids and harmful environmental contaminants. It has been shown that CYP3A alleles encoding enzymes with little or no activity ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.6.7.731
更新日期:2005-10-01 00:00:00
abstract::This review deals with the pharmacological properties of an alkylated monosaccharide mimetic, N-butyldeoxynojirimycin (NB-DNJ). This compound is of pharmacogenetic interest because one of its biological effects in mice - impairment of spermatogenesis, leading to male infertility - depends greatly on the genetic backgr...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.9.6.717
更新日期:2008-06-01 00:00:00
abstract:AIM:This study aims to evaluate the association between the MTRR rs1801394 alone or in interaction with the MTHFR rs1801133 and susceptibility to colorectal cancer (CRC) and its characteristics in Iranian population. Additionally, both a systematic review and meta-analysis were performed to derive a more precise assess...
journal_title:Pharmacogenomics
pub_type: 杂志文章,meta分析
doi:10.2217/pgs-2017-0030
更新日期:2017-07-01 00:00:00
abstract:AIM:Association of the brain-derived neurotrophic factor (BDNF) genetic polymorphism rs6265 (Val66Met) with methamphetamine (METH) dependence and METH-induced psychosis was investigated in the Thai population. MATERIALS & METHODS:The rs6265 genotype was determined in 100 male METH-dependent subjects and 102 controls u...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.96
更新日期:2015-01-01 00:00:00
abstract::This narrative review describes implementation, current status and perspectives of a pharmacogenomic (PGx) program at the Brazilian National Cancer Institute (INCA), targeting the cancer chemotherapeutic drugs - fluoropyrimidines, irinotecan and thiopurines. This initiative, designed as a research project, was support...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2020-0016
更新日期:2020-06-01 00:00:00
abstract:AIMS:Variant alleles of the CYP2C19 gene were recently associated with survival in breast cancer patients on tamoxifen therapy. CYP2C19 is one of the enzymes involved in the metabolism of tamoxifen into active metabolites. We investigated the hypothesis that CYP2C19*2 and *3 variants, known for their lack of enzyme act...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.10.112
更新日期:2010-10-01 00:00:00